Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25.
Radar 88 (high attention) · dilution pressure high · listing risk high · governance risk low · runway 1.9 mo · strongest signal: Exchange deficiency notice (Aug 21, 2026)
What would confirm: Nasdaq 'Pending Suspension' listing, Form 25, hearings-panel denial 8-K, or a reverse-split proxy.
What would prove it wrong: 8-K announcing regained compliance; equity raise that restores stockholders' equity; MVLS back above threshold for 10+ days.
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25. Exchange deficiency plus a structural reason cure is hard (sub-$5M float, negative equity, no cash, or a reverse split already used). Under Nasdaq's 2026 rules (one reverse split per 12 months; $5M MVLS floor with no cure period from Sept 2026) the usual escape hatches are narrower.
VivoSim Labs received a Nasdaq notice on July 24, 2026, stating it failed to maintain the $2.5 million minimum stockholders' equity requirement under Listing Rule 5550(b)(1), based on its March 31, 2026 fiscal year-end equity deficit of $(1.1) million. The company must submit a compliance plan by September 3, 2026, and may receive up to 180 days (until January 16, 2027) to cure. Despite closing a $4 million PIPE on July 17, 2026, and receiving a $5 million milestone payment from Eli Lilly in July 2026 (both post-balance-sheet events), the June 30, 2026 balance sheet still showed negative equity of $(2.3) million and cash of $1.67 million against a $10.8 million annual burn rate.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 80 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Aug 21, 2026 | ▼ Exchange deficiency notice | 8-K Item 3.01 filed 2026-08-21 (accepted 16:05 ET) filing | 59 |
| Aug 21, 2026 | ▼ Equity deficiency | “stockholders equity deficiency” language in 8-K (8-K) filed 2026-08-21 filing | 52 |
| Aug 21, 2026 | ▼ Minimum bid deficiency | “min bid” language in 8-K (8-K) filed 2026-08-21 filing | 48 |
| Aug 21, 2026 | ▼ Delisting language | “delisting notice” language in 8-K (8-K) filed 2026-08-21 filing | 46 |
| Aug 21, 2026 | ▼ Reverse split | “reverse split” language in 8-K (8-K) filed 2026-08-21 filing | 34 |
| Aug 21, 2026 | ▼ Reverse split | “reverse split” language in DEF 14A (DEF 14A) filed 2026-08-21 filing | 29 |
| Jun 30, 2026 | ▼ Share count +25% | Shares outstanding 3,494,071 (2026-07-10) -> 14,850,612 (2026-08-10), +325% filing | 46 |
| Jun 30, 2026 | ▼ Runway < 6 months | ~1.9 months runway: liquidity $1,670,000 as of 2026-06-30, burn $10,827,000/yr (latest fiscal-year operating cash flow (quarter too short to annualize) [companyfacts]) filing | 42 |
| Jun 30, 2026 | ▼ Negative equity | Stockholders' equity $-2,346,000 as of 2026-06-30 filing | 31 |
AUID authID Inc. · SOBR SOBR Safe, Inc. · DAIC CID Holdco, Inc. · DFLI Dragonfly Energy Holdings Co · SDST Stardust Power Inc. · ADIL ADIAL PHARMACEUTICALS, INC. · screener →